Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study

Background and Objectives: Mortality and illness due to COVID-19 have been linked to a condition known as cytokine release syndrome (CRS) that is characterized by excessive production of inflammatory cytokines, particularly interleukin-6 (IL-6). Tocilizumab (TCZ), a recent IL-6 antagonist, has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahem, Hoda Younes, Aly, Doaa Hamdy, Warda, Ahmed E. Abou, Farahat, Ramadan Abdelmoez, Youssef, Raghda Mamdouh, Abdelhamid, Mona Hassan, Goud, Heba Ahmed, Mohamed, Rana Ragab, Eldien, Menna Allah Y. Nasr, Alotaibi, Fahad Obaid, Alzarea, Abdulaziz Ibrahim, Alanazi, Abdullah Salah, Eisa, Nehal M., Refaee, Abdelrahman SH.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864835/
https://www.ncbi.nlm.nih.gov/pubmed/36676678
http://dx.doi.org/10.3390/medicina59010053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864835/
https://www.ncbi.nlm.nih.gov/pubmed/36676678
http://dx.doi.org/10.3390/medicina59010053

Ejemplares similares